Pharmacy and Therapeutics June 2016 : Cover 1

Register and Formulary Visit At Product June 2016 Volume 41 Number 6 For A Peer-Reviewed Journal for Managed Care and Formulary Management Decision-Makers Data Early Biosimilars Face Hurdles to Acceptance The FDA Has Approved Few, So Lack of Competition Is Keeping Prices High S. Barlas VISIT US ONLINE AT WWW.PTCOMMUNITY.COM HEALTH CARE & LAW Biosimilars: Still Not Quite Ready for Prime Time M. M. Rumore, PharmD, JD, MS, LLM, FAPhA; and F. R. Vogenberg, PhD, RPh, FASHP CASE REPORT Homicidality and Psychosis Caused by an Over-the-Counter Performance-Enhancing Supplement Containing Dendrobium Extract and L-Dopa A. Flynn, MD, PhD; J. Lincoln, MD; and M. Burke, MD, PhD DRUG FORECAST Dulaglutide (Trulicity) The Third Once-Weekly GLP-1 Agonist L. L. Smith, PharmD, CPh, MBA; J. F. Mosley II, PharmD, CPh, AAHIVP; C. Parke, PharmD; J. Brown, PharmD; L. S. Barris, PharmD; and L. D. Phan, PharmD A Pilot Study Comparing Hospital Readmission Rates in Patients Receiving Rivaroxaban or Enoxaparin After Orthopedic Surgery M. A. Herschman, PharmD, BCPS; F. S. Rigelsky, PharmD, BCPS; and S. S. Axtell, PharmD, BCPS MEETING HIGHLIGHTS American Association for Cancer Research W. Alexander

Next Page

Publication List
Using a screen reader? Click Here